BioSpace News Archive

- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, announced updates on its proprietary and partnered neurology programs at AES2020, the virtual Annual Meeting of the American Epilepsy Society. Dr. Simon Pimstone, Xenon’s Chief Executive Officer, said, “We continue to make exciting advances as both our proprietary and partnered neurology pipeline candidates progress into mid- to late-stage clin

Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced its CEO, Maria Maccecchini, Ph.D., will present at Benzinga’s inaugural Global SmallCap Conference on Tuesday, December 8, 2020 at 4:30 pm ET. Investors interested in viewing Annovis Bio’s presentation may register with free access here for the two-day

-- In a Randomized Investigator Sponsored Study, XPOVIO in Combination with Standard Induction and Consolidation Chemotherapy Demonstrated Improved Survival in Older, Fit Patients with Acute Myeloid Leukemia - -- Company to Host Virtual Investor and Analyst Event on Tuesday, December 8th at 1:00 PM ET to Review Highlights from the Data Presented at ASH 2020 --

Achieve Life Sciences, Inc. announced the closing of an underwritten public offering of 2,472,500 shares of its common stock at a public offering price of $7.00, for total gross proceeds of $17.3 million, prior to deducting underwriting discounts and commissions and estimated offering expenses.

Regulated medical device reprocessing is an important tool in improving environmental and public health outcomes, according to a new analysis published in Health Affairs.

Lannett Company, Inc. announced the closing of a $30 million asset-backed revolving credit facility with Wells Fargo Bank, National Association.

Triphase Accelerator, a private drug development company dedicated to advancing novel compounds through clinical proof-of-concept, today announced positive results from its ongoing Phase 1 multi-center, open-label, monotherapy study of TRPH-222 in heavily pre-treated patients with relapsed and/or refractory (R/R) B-cell lymphoma.

Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the promotion of Jacqueline (Jackie) Zummo, Ph.D., MPH, MBA from Senior Vice President, Research and Development Operations to Chief Scientific Operations Officer.

Bristol Myers Squibb (NYSE: BMY) today announced new results from the QUAZAR® AML-001 study presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, evaluating Onureg®

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that four oral presentations and six poster presentations containing clinical data and analyses related to imetelstat, the Company’s first-in-class telomerase inhibitor, were presented at the 62nd American Society of Hematology (ASH) Annual Meeting.